FINAL - LUPUS (SLE) & SCLERODERMA
(SYSTEMIC SCLEROSIS) QUESTIONS
WITH COMPLETE ANSWERS
Which aainformation aaabout aaplasmapheresis aawould aathe aanurse aainclude aain aathe
aateaching aaplan aafor aaa aapatient aadiagnosed aawith aasystemic aalupus aaerythematosus
aa(SLE)? aa
a. aaPlasmapheresis aacounteracts aarecovery aaof aaIgG aaproduction. aa
b. aaPlasmapheresis aaremoves aaeosinophils aaand aabasophils aafrom aathe aablood. aa
c. aaPlasmapheresis aadecreases aathe aadamage aato aaorgans aafrom aaT aalymphocytes.
aa
d. aaPlasmapheresis aaprevents aainflammatory aamediators aafrom aainjuring aatissues. aa-
aaAnswer aaANS: aaD aa
Plasmapheresis aais aaused aain aaSLE aato aaremove aaantibodies, aaantibody-antigen
aacomplexes, aaand aainflammatory aamediators, aasuch aaas aacomplement, aafrom aathe
aablood. aaT aalymphocytes, aaforeign aaantibodies, aaeosinophils, aaand aabasophils aado
aanot aadirectly aacontribute aato aathe aatissue aadamage aain aaSLE. aaImmunosuppressive
aatherapy aais aaused aato aaprevent aarecovery aaof aaIgG aaproduction.
A aapatient aawith aasystemic aalupus aaerythematosus aahas aabeen aaprescribed aa2
aaweeks aaof aahigh-dose aaprednisone aatherapy. aaWhich aainformation aaabout aathe
aaprednisone aais aamost aaimportant aafor aathe aanurse aato aainclude? aa
a. aa―Weigh aayourself aadaily aato aamonitor aafor aaweight aagain.
b. aa―The aaprednisone aadose aashould aabe aadecreased aagradually.
c. aa―A aaweight-bearing aaexercise aaprogram aawill aahelp aaminimize aarisk aafor
aaosteoporosis. aad. aa―Call aathe aahealth aacare aaprovider aaif aayou aahave aamood
aachanges aawith aathe aaprednisone. aa- aaAnswer aaANS: aaB aa
Acute aaadrenal aainsufficiency aamay aaoccur aaif aaexogenous aacorticosteroids aaare
aasuddenly aastopped. aaMood aaalterations aaand aaweight aagain aaare aapossible
aaadverse aaeffects aaof aacorticosteroid aause, aabut aathese aaare aanot aalife-threatening
aaeffects. aaOsteoporosis aaoccurs aawhen aapatients aatake aacorticosteroids aafor aalonger
aaperiods.
Which aastatement aaby aaa aapatient aawith aasystemic aalupus aaerythematosus aa(SLE)
aaindicates aathe aapatient aaunderstands aathe aanurse's aateaching aaabout aathe
aacondition? aa
, a. aa―I aawill aaexercise aaeven aaif aaI aaam aatired.
b. aa―I aawill aause aasunscreen aawhen aaI aaam aaoutside.
c. aa―I aashould aaavoid aanonsteroidal aaantiinflammatory aadrugs. aa
d. aa―I aashould aatake aabirth aacontrol aapills aato aaavoid aagetting aapregnant. aa- aaAnswer
aaANS: aaB aa
Severe aaskin aareactions aacan aaoccur aain aapatients aawith aaSLE aawho aaare aaexposed
aato aathe aasun. aaPatients aawould aaavoid aafatigue aaby aabalancing aaexercise aawith
aarest aaperiods aaas aaneeded. aaOral aacontraceptives aacan aaexacerbate aalupus.
aaAspirin aaand aanonsteroidal aaantiinflammatory aadrugs aaare aaused aato aatreat aathe
aamusculoskeletal aamanifestations aaof aaSLE.
A aa25-yr-old aafemale aapatient aawith aasystemic aalupus aaerythematosus aa(SLE) aahas
aaa aafacial aarash aaand aaalopecia. aaShe aatells aathe aanurse, aa―I aanever aaleave aamy
aahouse aabecause aaI aahate aathe aaway aaI aalook." aaWhich aapatient aaproblem aawould
aathe aanurse aaplan aato aaaddress? aa
a. aaActivity aaintolerance aa
b. aaImpaired aasocialization aa
c. aaImpaired aatissue aaintegrity aa
d. aaImpaired aacommunication aa- aaAnswer aaANS: aaB aa
The aapatient's aastatement aaabout aanot aagoing aaanywhere aabecause aaof aahating aathe
aaway aahe aaor aashe aalooks aaexpresses aaimpaired aasocialization, aaan aainsufficient
aaquantity aaof aahuman aaInteraction, aabecause aaof aaembarrassment aaabout aathe
aaeffects aaof aathe aaSLE. aaActivity aaintolerance aais aaa aapossible aaproblem aafor
aapatients aawith aaSLE, aabut aathe aainformation aaabout aathis aapatient aadoes aanot
aasupport aathis. aaThe aarash aawith aaSLE aadoes aanot aaimpair aatissue aaintegrity. aaThere
aais aano aaevidence aaof aaimpaired aacommunication aaability aafor aathis aapatient.
A aanew aaclinic aapatient aawith aajoint aaswelling aaand aapain aais aahaving aadiagnostic
aatests. aaWhich aatest aawould aathe aanurse aaidentify aaas aaspecific aato aasystemic aalupus
aaerythematosus? aa
a. aaRheumatoid aafactor aa(RF) aa
b. aaAntinuclear aaantibody aa(ANA) aa
c. aaAnti-Smith aaantibody aa(Anti-Sm) aa
d. aaLupus aaerythematosus aa(LE) aacell aaprep aa- aaAnswer aaANS: aaC aa
The aaanti-Sm aais aaantibody aafound aaalmost aaexclusively aain aaSLE. aaThe aaother
aablood aatests aaare aaalso aaused aain aascreening aabut aaare aanot aaas aaspecific aato
aaSLE.
The aahealth aacare aaprovider aahas aaprescribed aathe aafollowing aainterventions aafor aaa
aapatient aawho aais aataking aaazathioprine aa(Imuran) aafor aasystemic aalupus
aaerythematosus. aaWhich aaorder aawould aathe aanurse aaquestion? aa
a. aaDraw aaanti-DNA aablood aatiter. aa
b. aaAdminister aavaricella aavaccine. aa
(SYSTEMIC SCLEROSIS) QUESTIONS
WITH COMPLETE ANSWERS
Which aainformation aaabout aaplasmapheresis aawould aathe aanurse aainclude aain aathe
aateaching aaplan aafor aaa aapatient aadiagnosed aawith aasystemic aalupus aaerythematosus
aa(SLE)? aa
a. aaPlasmapheresis aacounteracts aarecovery aaof aaIgG aaproduction. aa
b. aaPlasmapheresis aaremoves aaeosinophils aaand aabasophils aafrom aathe aablood. aa
c. aaPlasmapheresis aadecreases aathe aadamage aato aaorgans aafrom aaT aalymphocytes.
aa
d. aaPlasmapheresis aaprevents aainflammatory aamediators aafrom aainjuring aatissues. aa-
aaAnswer aaANS: aaD aa
Plasmapheresis aais aaused aain aaSLE aato aaremove aaantibodies, aaantibody-antigen
aacomplexes, aaand aainflammatory aamediators, aasuch aaas aacomplement, aafrom aathe
aablood. aaT aalymphocytes, aaforeign aaantibodies, aaeosinophils, aaand aabasophils aado
aanot aadirectly aacontribute aato aathe aatissue aadamage aain aaSLE. aaImmunosuppressive
aatherapy aais aaused aato aaprevent aarecovery aaof aaIgG aaproduction.
A aapatient aawith aasystemic aalupus aaerythematosus aahas aabeen aaprescribed aa2
aaweeks aaof aahigh-dose aaprednisone aatherapy. aaWhich aainformation aaabout aathe
aaprednisone aais aamost aaimportant aafor aathe aanurse aato aainclude? aa
a. aa―Weigh aayourself aadaily aato aamonitor aafor aaweight aagain.
b. aa―The aaprednisone aadose aashould aabe aadecreased aagradually.
c. aa―A aaweight-bearing aaexercise aaprogram aawill aahelp aaminimize aarisk aafor
aaosteoporosis. aad. aa―Call aathe aahealth aacare aaprovider aaif aayou aahave aamood
aachanges aawith aathe aaprednisone. aa- aaAnswer aaANS: aaB aa
Acute aaadrenal aainsufficiency aamay aaoccur aaif aaexogenous aacorticosteroids aaare
aasuddenly aastopped. aaMood aaalterations aaand aaweight aagain aaare aapossible
aaadverse aaeffects aaof aacorticosteroid aause, aabut aathese aaare aanot aalife-threatening
aaeffects. aaOsteoporosis aaoccurs aawhen aapatients aatake aacorticosteroids aafor aalonger
aaperiods.
Which aastatement aaby aaa aapatient aawith aasystemic aalupus aaerythematosus aa(SLE)
aaindicates aathe aapatient aaunderstands aathe aanurse's aateaching aaabout aathe
aacondition? aa
, a. aa―I aawill aaexercise aaeven aaif aaI aaam aatired.
b. aa―I aawill aause aasunscreen aawhen aaI aaam aaoutside.
c. aa―I aashould aaavoid aanonsteroidal aaantiinflammatory aadrugs. aa
d. aa―I aashould aatake aabirth aacontrol aapills aato aaavoid aagetting aapregnant. aa- aaAnswer
aaANS: aaB aa
Severe aaskin aareactions aacan aaoccur aain aapatients aawith aaSLE aawho aaare aaexposed
aato aathe aasun. aaPatients aawould aaavoid aafatigue aaby aabalancing aaexercise aawith
aarest aaperiods aaas aaneeded. aaOral aacontraceptives aacan aaexacerbate aalupus.
aaAspirin aaand aanonsteroidal aaantiinflammatory aadrugs aaare aaused aato aatreat aathe
aamusculoskeletal aamanifestations aaof aaSLE.
A aa25-yr-old aafemale aapatient aawith aasystemic aalupus aaerythematosus aa(SLE) aahas
aaa aafacial aarash aaand aaalopecia. aaShe aatells aathe aanurse, aa―I aanever aaleave aamy
aahouse aabecause aaI aahate aathe aaway aaI aalook." aaWhich aapatient aaproblem aawould
aathe aanurse aaplan aato aaaddress? aa
a. aaActivity aaintolerance aa
b. aaImpaired aasocialization aa
c. aaImpaired aatissue aaintegrity aa
d. aaImpaired aacommunication aa- aaAnswer aaANS: aaB aa
The aapatient's aastatement aaabout aanot aagoing aaanywhere aabecause aaof aahating aathe
aaway aahe aaor aashe aalooks aaexpresses aaimpaired aasocialization, aaan aainsufficient
aaquantity aaof aahuman aaInteraction, aabecause aaof aaembarrassment aaabout aathe
aaeffects aaof aathe aaSLE. aaActivity aaintolerance aais aaa aapossible aaproblem aafor
aapatients aawith aaSLE, aabut aathe aainformation aaabout aathis aapatient aadoes aanot
aasupport aathis. aaThe aarash aawith aaSLE aadoes aanot aaimpair aatissue aaintegrity. aaThere
aais aano aaevidence aaof aaimpaired aacommunication aaability aafor aathis aapatient.
A aanew aaclinic aapatient aawith aajoint aaswelling aaand aapain aais aahaving aadiagnostic
aatests. aaWhich aatest aawould aathe aanurse aaidentify aaas aaspecific aato aasystemic aalupus
aaerythematosus? aa
a. aaRheumatoid aafactor aa(RF) aa
b. aaAntinuclear aaantibody aa(ANA) aa
c. aaAnti-Smith aaantibody aa(Anti-Sm) aa
d. aaLupus aaerythematosus aa(LE) aacell aaprep aa- aaAnswer aaANS: aaC aa
The aaanti-Sm aais aaantibody aafound aaalmost aaexclusively aain aaSLE. aaThe aaother
aablood aatests aaare aaalso aaused aain aascreening aabut aaare aanot aaas aaspecific aato
aaSLE.
The aahealth aacare aaprovider aahas aaprescribed aathe aafollowing aainterventions aafor aaa
aapatient aawho aais aataking aaazathioprine aa(Imuran) aafor aasystemic aalupus
aaerythematosus. aaWhich aaorder aawould aathe aanurse aaquestion? aa
a. aaDraw aaanti-DNA aablood aatiter. aa
b. aaAdminister aavaricella aavaccine. aa
